Eli Lilly And Co (LLY) Stock: Gains On Improved OSS In Breast Cancer


Eli Lilly And Co (NYSE: LLY) is having a strong time in the pre-market hours at the moment, and for good reason. The company released data with regard to a clinical stage treatment for breast cancer, showing improved overall survival rates. As a result, investor excitement ensued and the stock started to climb. Of course, our partners at Trade Ideas were the first to notify us of the gains. At the moment, LLY is trading at $83.26 per share after a gain of $1.37 per share or 1.67% thus far.

LLY Releases Positive Data

As mentioned above, Eli Lilly And Co is having an incredibly strong start to the day today in the pre-market hours as the result of news surrounding a late-stage clinical trial. The trial surrounds abemaciclib in combination with an aromatase inhibitor. According to the release, the combination treatment has improved overall survival rates in patients fighting advanced breast cancer. The company also expects that the treatment will be effective in treating other cancers such as lung cancer, brain metastases and pancreatic cancer.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LLY. In particular, we’ll be watching the ongoing work surrounding abemaciclib. Considering the overwhelmingly positive data surrounding the treatment, this could become a major revenue driver for the company moving forward. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

For sidebar:


Please enter your comment!
Please enter your name here